Literature DB >> 11558997

Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation.

G Zhou1, R Cummings, J Hermes, D E Moller.   

Abstract

Nuclear receptors (NRs) are a superfamily of ligand-dependent transcription factors that mediate the effects of hormones and other endogenous ligands to regulate the expression of specific genes. NRs are clearly important targets for drug discovery. Ligand-dependent protein-protein interactions between NRs and NR coactivators (NRCoAs) are a critical step in regulation of transcription. Homogeneous time-resolved fluorescence (HTRF) energy transfer technology is sensitive, homogeneous, and nonradioactive. These characteristics make this approach attractive for developing high-throughput screening assays. The long-lived nature of the fluorescence of europium cryptate combined with a time delay in reading facilitates the homogeneous nature of the assay. Importantly, the introduction of lanthanides (with R0 values as great as 90 A in HTRF) make HTRF amenable to be used for protein-protein interactions. In this article we review, using peroxisome proliferator-activated receptor (PPAR)gamma as a model system, a novel approach for characterizing the ligand-dependent interaction between NR and NRCoA using HTRF technology and its potential uses in small-molecule screening, profiling selectivity of NR-NRCoA paired interactions, and profiling NR ligands as agonists versus partial agonists or antagonists. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558997     DOI: 10.1006/meth.2001.1215

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

1.  Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase.

Authors:  Kui Xu; Charles Belunis; Wei Chu; David Weber; Frank Podlaski; Kuo-Sen Huang; Steven I Reed; Lyubomir T Vassilev
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

2.  Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Authors:  Craig Fenwick; Ma'an Amad; Murray D Bailey; Richard Bethell; Michael Bös; Pierre Bonneau; Michael Cordingley; René Coulombe; Jianmin Duan; Paul Edwards; Lee D Fader; Anne-Marie Faucher; Michel Garneau; Araz Jakalian; Stephen Kawai; Louie Lamorte; Steven LaPlante; Laibin Luo; Steve Mason; Marc-André Poupart; Nathalie Rioux; Patricia Schroeder; Bruno Simoneau; Sonia Tremblay; Youla Tsantrizos; Myriam Witvrouw; Christiane Yoakim
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

3.  Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.

Authors:  Arjen Koppen; Rene Houtman; Dirk Pijnenburg; Ellen H Jeninga; Rob Ruijtenbeek; Eric Kalkhoven
Journal:  Mol Cell Proteomics       Date:  2009-07-10       Impact factor: 5.911

4.  Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.

Authors:  James D Joseph; Bryan M Wittmann; Mary A Dwyer; Huaxia Cui; Delita A Dye; Donald P McDonnell; John D Norris
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-02       Impact factor: 11.205

5.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.

Authors:  Stephen M Soisson; Gopalakrishnan Parthasarathy; Alan D Adams; Soumya Sahoo; Ayesha Sitlani; Carl Sparrow; Jisong Cui; Joseph W Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

6.  Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

Authors:  Min-Chul Cho; Kyoung Lee; Sang-Gi Paik; Do-Young Yoon
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

7.  Systematic analyses of the cytotoxic effects of compound 11a, a putative synthetic agonist of photoreceptor-specific nuclear receptor (PNR), in cancer cell lines.

Authors:  Zibo Zhao; Lu Wang; Zhi Wen; Serife Ayaz-Guner; Yidan Wang; Paul Ahlquist; Wei Xu
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.